Fiera Capital Corp Has $421.39 Million Stock Position in Johnson & Johnson $JNJ

Fiera Capital Corp cut its stake in Johnson & Johnson (NYSE:JNJ) by 5.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,758,667 shares of the company’s stock after selling 154,749 shares during the period. Johnson & Johnson comprises approximately 1.4% of Fiera Capital Corp’s holdings, making the stock its 21st largest holding. Fiera Capital Corp owned approximately 0.11% of Johnson & Johnson worth $421,386,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Citigroup lifted their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. UBS Group upped their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, HSBC raised their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE:JNJ opened at $194.52 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market cap of $468.65 billion, a price-to-earnings ratio of 18.78, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a 50 day moving average of $185.13 and a 200-day moving average of $169.48. Johnson & Johnson has a one year low of $140.68 and a one year high of $195.55.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.